中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Metabolic Diseases Exploratory Indications
  • Pipeline
    Pipeline Clinical Trials
  • Partnership
  • Investors
    Financials & Filing
  • News
  • Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Show More
    2014
  • First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial

    2020-12-28

  • Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

    2020-12-22

  • Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

    2020-12-14

  • Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

    2020-12-04

  • Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

    2020-11-30

  • ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

    2020-11-19

  • Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH

    2020-11-18

  • Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

    2020-10-12

  • Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

    2020-10-10

  • Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

    2020-09-14

 
  • 1
  • 2
  • 3
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • All Rights Reserved

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1